Topiramate and Zonisamide Linked to Increased Risk of Symptomatic Kidney Stones, suggests study
A new study published in the American Journal of Kidney Diseases showed that Topiramate and zonisamide, which are often taken for obesity, epilepsy, and migraines, may increase the risk of kidney stones.
General practitioners are increasingly using topiramate and zonisamide, which were first created as antiseizure drugs, for various purposes including managing weight or preventing migraines. Although there is a paucity of empirical evidence supporting this link, topiramate and zonisamide may both contribute to kidney stone development by raising urine pH and lowering urine citrate. Thus, this study by Bassel Salka and colleagues investigated the association between kidney stone risk and the usage of topiramate and zonisamide.
Age- and sex-matched controls were chosen for this retrospective cohort study, which included Medicare enrollees and people in Optum's deidentified Clinformatics Data Mart Database (CDM) who had at least one prescription filled for topiramate or zonisamide between January 1, 2011, and September 30, 2019.
The exposure criteria were either new usage of zonisamide or topiramate. The main outcome was determined to be a symptomatic stone occurrence, which is defined as a visit to the emergency room, hospitalization, or kidney stone surgery. The primary analytical method was Cox proportional hazards regression.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.